Last year's ASH conference (Kyle LaHucik for Endpoints News)
November 3, 2023 10:50 AM EDTUpdated November 9, 02:10 PM
R&D

In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

Max Gelman

Senior Editor

The non-late break­ing ab­stracts for next month’s Amer­i­can So­ci­ety of Hema­tol­ogy meet­ing were re­leased on Thurs­day, giv­ing a peek in­to what will be some of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times